Teva Pharmaceutical Industries (TEVA) said Tuesday that it has exercised its right to further raise the pool tender cap for its pool 3 notes to a total purchase price of $400 million from $350 million previously.
The pool 3 notes consist of US dollar-denominated 7.875% sustainability-linked senior notes due 2029, Euro-denominated 7.375% sustainability-linked senior notes due 2029, and US dollar-denominated 8.125% sustainability-linked senior notes due 2031, the company added.
Teva said the pool tender caps for the pool 1 notes, which consist of US dollar-denominated 3.150% senior notes due 2026, and the pool 2 notes, which consist of US dollar-denominated 4.750% sustainability-linked senior notes due 2027 and Euro-denominated 3.750% sustainability-linked senior notes due 2027, remain unchanged.
The combined total purchase price of the notes is increased to $2.30 billion from $2.25 billion, Teva said.
A total of $2.60 billion of the pool 1 notes have been tendered, while a total of $1.39 billion of the pool 2 notes and $717.6 million of the pool 3 notes have been tendered so far as part of early tender offer results, Teva said, adding that the tender offers will expire on June 17.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。